DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients With Minimal Residual Disease

Eligibility Criteria

• * Age ≥ 18 years at the time of study entry
• * ECOG 0-1
• * Histologically documented high-risk stage II, stage III, or stage IV colorectal adenocarcinoma with no evidence of disease following definitive local therapy (including surgical resection or ablation)
• * No radiographic evidence of disease by contrast enhanced CT chest/abdomen/pelvis
• * Presence of detectable ctDNA mutation that matches mutations found in tumor tissue
• * Completion of all standard of care adjuvant therapy
• * Platelet count \>50,000
• * Ability to give informed consent
• * Ability to complete all questionnaires involved in study
• * Concurrent malignancy under active treatment
• * Known active gastrointestinal bleeding or peptic ulcer disease
• * Known hypersensitivity to vitamin D or aspirin
• * CrCl\<30 mL/min within 30 days of starting the intervention
• * Current usage of therapeutic anticoagulation (warfarin, Eliquis, Xarelto)
• * Inability to safely participate in physical activity in the opinion of the treating oncologist
• * Pregnant or nursing women. N.B.: urine pregnancy test will be administered as part of the screening process.
• * Persistent hypercalcemia or conditions predisposing to hypercalcemia (i.e., hyperparathyroidism)
• * Known symptomatic genitourinary stones